Atacicept in Multiple Sclerosis Extension Study, Phase II

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\]

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Atacicept 25 mg
DRUG: Atacicept 75 mg
DRUG: Atacicept 150 mg
DRUG: Atacicept 150 mg

Sponsor

EMD Serono

Collaborators

[object Object]